Specialized Adenovirus Vectors for Niche Applications

This inventive concept adapts adenovirus vectors derived from chimpanzee adenovirus AdY25 for specific, narrow markets or unique operational environments, such as high-security biodefense, disaster relief, or extreme weather conditions.

The original patent disclosed adenovirus vectors with various modifications, but these vectors may not be suitable for specialized applications. This inventive concept addresses the need for adenovirus vectors tailored to specific, high-stakes scenarios, such as biodefense or disaster relief, where rapid deployment, high security, or adaptability to extreme conditions are crucial.

The inventive concept comprises adenovirus vectors with capsids derived from chimpanzee adenovirus AdY25, encapsidating nucleic acid molecules with exogenous nucleotide sequences of interest operably linked to expression control sequences. These vectors are designed for use in high-security biodefense applications, rapid vaccine deployment in disaster relief scenarios, protection against infectious diseases in extreme weather conditions, or remote areas. The vectors can be produced using a portable production unit, lyophilized for storage and transportation, and reconstituted on-site. A modular production system enables customized vaccine development for specialized applications.

The new claims introduce novel adaptations of the original adenovirus vectors for specific, high-stakes scenarios, providing a non-obvious solution to the limitations of the original patent. The inventive concept's novelty lies in its tailored approach to address the unique challenges of these niche applications.

Alternative embodiments of the inventive concept could include adenovirus vectors with different capsid protein combinations, nucleic acid molecules with varying exogenous sequences, or modified expression control sequences. Variations could also involve different production methods, such as using alternative host cells or scalable manufacturing processes.

The inventive concept has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the areas of biodefense, disaster relief, and infectious disease prevention. Target markets include government agencies, non-profit organizations, and private companies involved in emergency response, public health, and vaccine development.